CDKN1B and cancer: miR-222 can play a role as an onco-miR in some cancer types, such as cervical cancer [13], prostate carcinoma [14], since it can target tumor suppressors, such as PTEN [13, 15], p27Kip1 [14], and TIMP3 [15], promoting the proliferation, migration and invasion of cancer cells.